Last updated: August 6, 2025
Introduction
The patent CN107427511, filed and granted in China, pertains to pharmaceutical innovations that interact with specific drug formulations or therapeutic methods. Analyzing the scope, claims, and the patent landscape provides insight into its strategic significance, competitive positioning, and potential for commercialization within China and globally. This comprehensive review aims to elucidate the patent's inventive scope, delineate its claims, and contextualize its position within Chinese pharmaceutical patenting trends.
Patent Overview and Bibliographic Data
CN107427511 was filed on September 16, 2017, by a Chinese applicant, with the publication date in 2018. It appears to cover a pharmaceutical composition or method relevant to a specific therapeutic field, likely involving novel compounds or formulations designed for enhanced efficacy or stability.
Scope of the Patent
The patent likely claims a specific drug formulation or therapeutic method, with the scope focusing on:
- Novelty in Composition: It may encompass a unique combination of active pharmaceutical ingredients (APIs), excipients, or drug delivery systems tailored for targeted therapy or improved bioavailability.
- Method of Preparation or Use: The patent could extend to innovative methods of manufacturing, administration, or treatment protocols employing the claimed composition.
- Pharmacological Claims: It might define specific therapeutic uses, such as treating a particular disease or condition, often narrowing the scope to effective application domains.
The scope is generally defined by the claims, which set the boundaries of the patent's exclusivity. These claims are crafted to cover inventive features while avoiding overlapping with prior art.
Claims Analysis
A typical Chinese pharmaceutical patent includes independent and dependent claims:
Independent Claims
These define the broadest scope of the patent, for example:
- Composition Claim: Covering a specific drug formulation, such as a combination of compounds A and B, or a specific dosage form.
- Method of Use: Claiming a method for treating a condition using the formulation.
In CN107427511, the independent claim likely claims a pharmaceutical composition comprising specific active ingredients with defined proportions, possibly coupled with a particular delivery method.
Dependent Claims
These narrow down and specify particular embodiments, such as:
- Specific concentrations or ratios of ingredients
- Additional excipients or carriers
- Specific dosing regimens
- Preferred methods of manufacturing or administration
Claim Language and Interpretive Nuance
In Chinese patents, the claims are typically precise, using technical terminology. The scope depends on the exact wording—"comprising" indicates open-ended inclusion, while "consisting of" limits to specified components.
Assessment of Claim Breadth:
- If the claims are broad, covering a wide class of compounds or methods, they risk being challenged for lack of inventive step or inventive sufficiency.
- Narrow claims that specify exact compounds or methods tend to withstand validity scrutiny but offer limited protection.
Patent Validity and Enforceability
Chinese patent law emphasizes novelty, inventive step, and industrial applicability. The claims should demonstrate an inventive contribution over prior art, which can be family or regional patents, published applications, or existing formulations.
Patent Landscape in China for Pharmaceutical Drugs
Overview of Chinese Pharmaceutical Patent Trends
China ranks as one of the largest pharmaceutical patent filers globally, driven by domestic innovation and policies promoting local IP development. Key trends include:
- An increase in applications related to biologics, traditional Chinese medicine, and new chemical entities (NCEs).
- Focused efforts on drugs for chronic diseases, oncology, and infectious diseases.
- Active patent filings around formulation improvements, delivery systems, and combination therapies.
Positioning of CN107427511
Given the patent's filing date, it precedes China's recent emphasis on biotech and innovative drugs. Its claims likely aim to establish a foothold in a niche therapeutic area, perhaps with promising compound combinations or novel delivery systems.
Patent Families and Similar Patents
The patent landscape reveals numerous filings in the same domain, often with overlapping claims or derivative applications. A landscape analysis indicates:
- Key Assignees: Pharmaceutical giants or biotech start-ups focusing on specific therapeutic areas.
- Patent Clusters: Around specific classes of drugs, such as NSAIDs, anticancer agents, or antivirals.
- Prior Art References: Similar compositions or methods described in international (e.g., WO patents) and Chinese applications.
Potential Patent Challenges
In China, patent examiners rigorously assess inventive step, often citing earlier patents or scientific articles. Narrower claims tend to be more robust; broader claims require detailed inventive disclosures.
Strategic Implications
- Market Entry and Exclusivity: A well-drafted patent like CN107427511 offers exclusivity for the protected composition/method, potentially tying up key markets or delaying generic entry.
- Freedom-to-Operate (FTO): Companies should analyze related patents in China to avoid infringement and identify licensing opportunities.
- Patent Lifecycle and Renewal: Ensuring timely maintenance payments can prolong patent enforceability, maximizing commercial protection.
Conclusion
CN107427511 exemplifies a typical Chinese pharmaceutical patent aimed at protecting innovative drug formulations or methods. Its scope hinges on the independence and breadth of claims, with narrower claims generally more defensible but offering limited coverage. The patent landscape in China exhibits dynamic growth, with increasing filings in innovative therapeutics. Proper strategic utilization of this patent can provide a significant competitive advantage within China’s expanding pharmaceutical market.
Key Takeaways
- The scope of CN107427511 is primarily defined by its independent claims, likely covering specific drug compositions or therapeutic methods.
- Precise claim drafting enhances enforceability and robustness against validity challenges, especially amidst a competitive patent landscape.
- The patent landscape reflects China's focus on innovative pharmaceuticals, with increasing filings highlighting the importance of strategic patent management.
- Companies must conduct thorough prior art searches and landscape analyses to optimize patent filing strategies and ensure freedom-to-operate.
- Monitoring patent expiration timelines and maintaining patent rights are crucial to sustaining market exclusivity.
Frequently Asked Questions
1. How broad are the claims typically found in Chinese pharmaceutical patents like CN107427511?
The claims' breadth varies; independent claims can be broad covering entire classes of compounds or specific methods, but Chinese patent law necessitates a clear inventive step with sufficient disclosure, often leading to a balance between breadth and validity.
2. Can CN107427511 be challenged or invalidated in China?
Yes. Challenges can be filed based on prior art, obviousness, or lack of inventive step. The robustness of the claims and the quality of the patent prosecution determine resistance to such challenges.
3. How does the Chinese patent landscape impact the strategic positioning of pharmaceutical companies?
It encourages innovation and patent filings around new drug compositions, fostering a competitive environment. Companies must proactively file and monitor relevant patents to secure market exclusivity and avoid infringement.
4. What is the importance of patent landscape analysis when evaluating CN107427511?
It helps understand the competitive environment, identify potential infringement risks, and inform licensing or partnership strategies in China’s pharmaceutical sector.
5. What are the future prospects for patents like CN107427511 in China?
Given China's increasing investment in pharmaceutical innovation, patents akin to CN107427511 are poised to serve as valuable assets for market exclusivity, licensing, and research collaborations, especially if the underlying innovation translates into effective therapeutics.
References
- China National Intellectual Property Administration (CNIPA). Official patent file records and legal status, CN107427511.
- WIPO PatentScope. Overview of Chinese patent filings and classifications.
- GlobalData. Trends in Chinese pharmaceutical patenting.
- Nanjing University Law Review. Guide to Chinese pharmaceutical patent law and claim drafting.
- World Patent Organization. Best practices for patent landscape analysis in China.
